Evidence map›Paper›PMID 42756618›Full record

ArticleMaterials today. Bio2026

Porosity-engineered long-acting protopanaxadiol microspheres prevent CDK4/6 inhibitor-induced myelosuppression.

Anan Zhang, Yunjing Zhu, Xinyu Kong, Zixu Liu, Mengxia Tan, Hongyun Yu, Guanghui Jing, Jingxin Gou, Tian Yin, Haibing He and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anan ZhangDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Yunjing ZhuYantai Quanzhong Biomedical Research Institute, Yantai, Shandong, 264270, China.
Xinyu KongSchool of Pharmacy, Shandong Medical and Pharmaceutical University, Yantai, Shandong, 264003, China.
Zixu LiuSchool of Pharmacy, Yantai University, Yantai, Shandong, 264005, China.
Mengxia TanSchool of Pharmacy, Shandong Medical and Pharmaceutical University, Yantai, Shandong, 264003, China.
Hongyun YuYantai Quanzhong Biomedical Research Institute, Yantai, Shandong, 264270, China.
Guanghui JingYantai Quanzhong Biomedical Research Institute, Yantai, Shandong, 264270, China.
Jingxin GouDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Tian YinDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Haibing HeDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Yu ZhangDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Xuemei ZhangYantai Quanzhong Biomedical Research Institute, Yantai, Shandong, 264270, China.
Ke LiuShandong Boyuan Biomedical Co.,Ltd., Yantai, Shandong, 264670, China.
Peifu XiaoDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Xing TangDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CDK4/6 inhibitor-induced myelosuppression frequently necessitates treatment interruption or dose reduction, yet effective pharmacological interventions specifically addressing this persistent hematological toxicity remain limited. Here, we report a porosity-programmed protopanaxadiol-loaded PLGA microsphere (PPD-MS) system for rapid-onset and long-acting myeloprotection during anticancer treatment. Using a continuous-flow O/W microsphere fabrication strategy, microsphere porosity and core-shell architecture were precisely regulated by tuning aqueous-phase osmotic pressure, establishing a controllable process-structure-release relationship. The optimized PPD-MS rapidly achieved a stable plasma plateau within 0.5 h after intramuscular injection and maintained sustained systemic exposure for 19 days, with a strong in vitro-in vivo correlation between release profiles (R

Indexed as

CDK4/6 inhibitorsLong-acting drug deliveryMyelosuppressionPI3K/AKT–Rb/E2F1 signalingPorosity engineeringProtopanaxadiol-loaded PLGA microsphere

Identifiers

PMID42756618
PMCPMC13584051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.